Ardelyx
Manufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
400 5th Ave Ste 210, Waltham, Massachuse...Phone Number
(510) 745-1700Website
www.ardelyx.comRevenue
$427.7 MillionStock Symbol
ARDXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
4
1
1
1
1
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate for the management of hyperphosphatemia in adult patients with chronic kidney disease (CKD) on dialysis, which has completed three successful Phase 3 trials.Explore more
Ardelyx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ardelyx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Ardelyx, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Ardelyx is spiking on competitors!
Earning: See what the market has to say on Ardelyx recently announced quarterly report
Click to see if Ardelyx had a recent Job posting/layoffs
Product Launch: Get notified when Ardelyx launches new products
Funding: Get notified immidiatlly once Ardelyx has new funding data
Check if Ardelyx has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Ardelyx
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Ardelyx
Compare insights from companies similar to Ardelyx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$105.8M
501-1,000
Public
$222.7M
1998
KH
Keith HoeyGlobal Vice President, , Value, Access & Distribution
Company Profile Activity
Activity Insights
Ardelyx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ardelyx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ardelyx.
Ardelyx financials insights
Gather financial insights about Ardelyx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2008
Series A
$26M
2011
Series B
$30M
2014
Multiple Rounds
$100.8M
2015
Share Placement
$77.8M
2016
Stock Offering
$80.4M
Share Placement
$110M
2018
Debt
$50M
2022
Debt
$27.5M
Other Financing Round
$20M
Ardelyx Tech Stack
A closer look at the technologies used by Ardelyx
See more technologies
Most Recent Scoops
Hiring Plans
Ardelyx has more open roles in Human Resources than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Open Position
Open Position
Person-Based
Stake & Stock Ownership, Finance, Financial Transactions
Ardelyx News & Media
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 3 at 9:55 a.m. ET in New York.Ardelyx NKF data supports XPHOZAH safety - ARDX - Stock Titan
Across an 18-month extension and 26-week trial, researchers found no meaningful electrolyte shifts beyond phosphate reduction. NKF poster is now online.Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the presentation of a data analysis evaluating the long-term impact of XPHOZAH® (tenapanor) on serum electrolytes and selected nutrition biomarkers at the National Kidney Foundation’s (NKF) Spring Clinical Meetings, currently underway in New OrA Look At Ardelyx (ARDX) Valuation After Strong Q1 Results And Updated 2026 Guidance
Ardelyx (ARDX) just reported first quarter 2026 results, with revenue of US$94.47 million versus US$74.11 million a year earlier, a net loss of US$37.61 million and a loss per share of US$0.15. See our latest analysis for Ardelyx. The latest earnings update, management commentary and new Chief Legal Officer appointment appear to be feeding into fresh interest in the stock. A 1-day share price return of 8.69% and a 1-year total shareholder return of 66.59% indicate positive
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ardelyx
Sign Up For FreeTo access detailed company insights
Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate for the management of hype... Read More
